Section Reviews; Anti-infectives: Section Review Anti-infectives: Therapeutic potential of nonnucleoside reverse transcriptase inhibitors in the treatment of HIV infection

References to Primarv Literature

• BARRE-SINOUSSI F, CHERMANN JC, REY F et al.: Isolation of a T-Iymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 220:868–871.
   PubMed Web of Science ®Google Scholar
• GALLO RC, SARIN PS, GELMANN EP et al.: Isolation ofhuman T-cell leukemia virus in acquired immune defi-ciency syndrome (AIDS). Science (1983) 220:865–867.
   PubMed Web of Science ®Google Scholar
• POPOVIC M, SARNGHDHARAN MG, READ E, GALLO RC: Detection, isolation, and continuous production of cy-topathic retroviruses (HTLV-HI) from patients with AIDS and pre-AIDS. Science (1984) 224:497–500.
   PubMed Web of Science ®Google Scholar
• ALIZON M, WAIN-HOBSON S, MONTAGNIER L, SONIGO P: Genetic variability of the AIDS virus: nucleotide se-quence analysis of two isolates from African patients. Cell (1986) 46:63–74.
   PubMed Web of Science ®Google Scholar
• BALFE P, SIMMONDS P, LUDLAN CA, BISHOP JO, BROWN AJL: Concurrent evolution of human immunodeficiency virus type 1 in patients infected from the same source: rate of sequence change and low frequency of inactiv-ating mutations. J. Virol. (1990) 64:6221–6233.
   PubMed Web of Science ®Google Scholar
• HAHN BH, SHAW GM, TAYLOR ME et al: Genetic variation In HTLV-HI/LAV over time in patients with AIDS, or at risk for AIDS. Science (1986) 232:1548–1553.
   PubMed Web of Science ®Google Scholar
• BAKHANASHVILI M, HIZI A: The fidelity of reverse tran-scriptase of human immunodeficiency viruses, and murine leukemia virus, exhibited by the mispair extension frequencies, is sequence dependent and enzyme related. FEBS Lett. (1993)319:201–205.
   PubMed Web of Science ®Google Scholar
• BEBENEK K, KUNKEL TA: The fidelity of retroviral re-verse transcriptase. In: Reverse Transcriptase. Skalka AM, Goff SP (Eds.), Laboratory Press, Cold Spring Harbor, Plain-view, NY (1993):85–102.
   Google Scholar
• HUBNER A, KRUHOFFER M, GROSSE F, KRAUSS G: Fidelityof human immunodeficiency virus type 1 reverse tran-scriptase in copying natural RNA. J. Mol. Biol. (1992) 223:595–600.
   PubMedGoogle Scholar
• RICCHETTI M, BUC H: Reverse transcriptase and genomic variability: the accuracy of DNA replication is enzyme specific and sequence dependent. EMBO J. (1990) 9:1583–1593.
   PubMed Web of Science ®Google Scholar
• NOWAK M: HIV mutation rate. Nature (1990) 347:522.
   PubMed Web of Science ®Google Scholar
• PARKER WB AND CHENG YC: Mitochondrial toxicity ofantiviral nucleoside analogues. J. IVIH Res. (1994) 6:57–61.
   Google Scholar
• MARTIN JL, BROWN CE, MATTHEWS-DAVIES N, REARDON JE: Effects of antiviral nucleoside analogues on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob. Agents Chemother. (1994) 38:2743–2749.
   PubMed Web of Science ®Google Scholar
• CHEN C, CHENG Y: Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human inununodeficiency virus compound 2',3'-dideoxycytidine. Biol. Chem. (1989) 264:11934–11937.
   Web of Science ®Google Scholar
• KOHLSTAEDT LA, WANG J, FRIEDMAN JM, RICE PA, STEITZ •TA: Crystal structure at 3.51 resolution of 1I17-1 reverse transcriptase complexed with an inhibitor. Science (1992) 256:1783–1790.
   Google Scholar
• EL DIRANI-DIAB R, ANDREOLA ML, NEVINSKY G et al.: Biochemical characterization of the p51 subunit of human immunodeficiency virus reverse transcriptase In homo- and heterodknerk recombinant forms of the enzyme. FEBS letters (1992) 301:23–28.
   PubMed Web of Science ®Google Scholar
• BASU A, BASU S, MODAK MJ: Structure-activity analyses of MV-1 reverse transcriptase. Biochem. Biophys. Res. Comm. (1992) 183:1131–1138.
   PubMed Web of Science ®Google Scholar
• LEGRICE SFJ, NAAS T, WOHLGENSINGER B, SCHATZ O: Subunit-selective mutagenesis indicates minimal po-. lymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase. EMBO J (1991) 10:3905–3911.
   Google Scholar
• CHENG N, PAINTER GR, AND FURMAN PA: Crosslinking of substrates occurs exclusively to the p66 subunit of heterodimeric MV-1 reverse transcriptase Biochem. Biophys. Res. Comm. (1991) 174:785–789.
   PubMed Web of Science ®Google Scholar
• DIVITA G, RITTINGER K, GEOURJON C, DELEAGE G, GOODY R: Dimerization kinetics of HIV-1 and my-2 reverse transcriptase a two Step Process. J. Mot Biol. (1995) 245:508–521.
   PubMed Web of Science ®Google Scholar
• THIMMIG RE AND MCHENRY CS: Human immunodefic-iency virus reverse transcriptase. J. Biol. Chem. (1993) 268:16528–16536.
   PubMedGoogle Scholar
• JACQUES PS, WOHRL BM, HOWARD KJ, LE GRICE SF: Modulation of HIV-1 reverse transcriptase function in 'selectively deleted' p66/p51 heterodhners. J. Biol. Chem. (1994) 269:1388–1393.
   PubMed Web of Science ®Google Scholar
• GOEL R, BEARD WA, KUMAR A et al.: Structure/function studies ofreverse transcriptase: dimerization-de-fective mutant I289K. Biochemisby (1993) 32:13012–13018.
   PubMed Web of Science ®Google Scholar
• ZAKHAROVA OD, TARRAGO-LITVAK L et al.: Interaction of primer tRNA(Lys-3) with the p51 subunit of human inununodeficiency virus type 1 reverse transcriptase: a possible role in enzyme activation. FEBS Lett. (1995) 361:287–290
   PubMed Web of Science ®Google Scholar
• RICHTER-COOK NJ, HOWARD KJ, CIRINO NM, WOHRL BM, LE GRICE SF: Interaction of tRNA(Lys-3) with multiple forms of human immunodeficiency virus reverse tran-scriptase. J. Biol. Chem, (1992) 267:15952–15957.
   PubMed Web of Science ®Google Scholar
• HUANG SC, SMITH JR, MOEN LK: Contribution of the p51 subunit of mV-1 reverse transcriptase to enzyme proc-essivity. Biochem. Biophys. Res. Comm. (1992) 184:986–992.
   PubMed Web of Science ®Google Scholar
• JACOBO-MOLINA A, DING J, NANNI RG et al.: Crystal structure of human immunodeficiency virus type 1reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc. Natl. Acad. Sci. USA (1993) 90:6320–6324.
   Google Scholar
• PATEL PH, JACOBO-MOLINA A, DING J et at : Insights into DNA polymerisation mechanisms from structure andfunction analysis of HIV-1 reverse transcriptase. Bio-chemistry (1995) 34:5351–5363.
   Google Scholar
• ARNOLD E, JACOBO-MOLINA A, NANNI RG et al.: Structure of HIV-1 reverse transcriptase/DNA complex at 7 A resolution showing active site locations. Nature (1992) 357:85–89,
   PubMed Web of Science ®Google Scholar
• KATI WM, JOHNSON KA, JERVA LF, ANDERSON KS: Media-nism and fidelity of HIV reverse transcriptase. J. Biol.Chem. (1992) 267:25988–25997.
   Google Scholar
• REARDON JRI: Human immunodeficiency virus reverse transcriptase: steady-state and pre-steady-state kinetics of nucleotide incorporation. Biochemistry (1992) 31:4473–4479.
   PubMed Web of Science ®Google Scholar
• REARDON JE: Human immunodeficiency virus reverse transcriptase. a kinetic analysis of RNA-dependent and DNA-dependent DNA polymerisation. J. Biol. Chem. (1993) 268:8743–8751.
   Google Scholar
• HSIEH JC, Z1NNEN S, MODRICH P: Kinetic mechanism of the DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase. J Biol. Chem.(1993) 268:24607–24613.
   PubMed Web of Science ®Google Scholar
• MULLER B, RESTLE T, REINSTEIN J, GOODY RS: Interaction of fiuorescently labeled dicleoxynudeotides with HIV-1 reverse transcriptase. Biochemistry (1991) 30:3709–3715.
   PubMed Web of Science ®Google Scholar
• DIVITA G, MULLER B, IMMENDORFER U et al.: Kinetics of interaction of HIV reverse transcriptase with primer/template. Biochemistry (1993) 32:7966–7971.
   Google Scholar
• KRUHOFFER M, URBANKE C, GROSSE F: Two step binding of HIV-1 reverse transcriptase to nucleic add substrates. Nuc. Acid Res (1993) 21:3943–3949.
   PubMed Web of Science ®Google Scholar
• RODGERS DW, GAMBLIN SJ, HARRIS BA et al.: The structore of unliganded reverse transcriptase from the hu-man immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA (1995) 92:1222–1226.
   Google Scholar
• PATEL SS, WONG I, JOHNSON KA: Pre-steady-state kinetic analysis of processive DNA replication including com-plete characterization of an exonuclease-deficient mu-tant. Biochemistry (1991) 30:511–525.
   PubMed Web of Science ®Google Scholar
• WONG I, PATEL SS, JOHNSON KA: An induced-fit kinetic mechanism for DNA replication fidelity: direct measurement by single-turnover kinetics. Biochemistry(1991) 30:526–537.
   PubMed Web of Science ®Google Scholar
• JOHNSON KA: Conformational coupling in DNA polymerase information transfer [Review]. Philosophical Trans-actions of the Royal Society of London - Series B: Biological Sciences (1992) 336:107–112.
   Google Scholar
• MIZRAHI V, HENRIE RN, MARLIER JF, JOHNSON KA, BENK-OVIC SJ: Rate-limiting steps in the DNA polymerase I reaction pathway. Biochemistry (1985) 24:4010–4018.
   PubMed Web of Science ®Google Scholar
• STEITZ TA: DNA- and RNA-dependent DNA polymerases Curr. Opin. Struct. Biol. (1993) 3:31–38.
   Google Scholar
• PELLETIER H, SAWAYA MR, KUMAR A, WILSON S, KRAUT J: Structures of ternary complexes of rat DNA polym-erase B, a DNA template-primer, and ddCTP. Science (1994) 264:1891–1903.
   PubMed Web of Science ®Google Scholar
• GOPALAKRISHNAN V, PELISKA JA, BENKOVIC SJ: Human Immunodeficiency virus type 1 reverse transcriptase: spatial and temporal relationship between the polym-erase and RNase H activities. Proc. Natl. Acad. Sci. USA (1992) 89:10763–10767.
   PubMed Web of Science ®Google Scholar
• WOHRL BM, MOELL1NG K: Interaction of 11IV-1 ribonu-clease H with polypurirte tract containing RNA-DNA hybrids. Biochemistry (1990) 29:10141–10147.
   PubMedGoogle Scholar
• WOHRL BM, TANTILLO C, ARNOLD E, LE GRICE SFJ: An expanded model of replicating human immunodefi-ciency virus reverse transcriptase. Biochemistry (1995) 34:5343–5350.
   PubMed Web of Science ®Google Scholar
• METZGER W, HERMANN T, SCHATZ O, LE GRICE SF, HEUMANN H: Hydroxyl radical footprint analysis of human immunodeficiency virus reverse transcriptase-template primer complexes. Proc. Natl. Acad. Sci. USA (1993) 90:5909–5913.
   PubMed Web of Science ®Google Scholar
• PAUWELS R, ANDRIES K, DESMYTER J et al.: Potent and selective inhibition of HIV-1 replication In vitro by a novel series of T1BO derivatives. Nature (1990) 343:470–474.
   PubMed Web of Science ®Google Scholar
• MERLUZZI VJ, HARGRAVE ICD, LABADIA M et al.: Inhibi-tion of HIV-1 replication by a notmucleosicle reverse transcriptase inhibitor. Science (1990) 250:1411–1413.
   PubMed Web of Science ®Google Scholar
• DEBYSER 2, PAUWELS R, ANDRIES K et al.: An antiviral target on reverse transcriptase of human immunodefi-ciency virus type 1 revealed by tetrahydroimidazo-[4,5, 1-jk] [1,4]benzodiazepin-2 (111)-one and -thione deriva-tives. Proc. Natl, Acad. Sci. USA (1991) 88:1451–1455.
   Google Scholar
• ALTHAUS IW, CHOU JJ, GONZALES AJ et al.: Steady-statekinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E. J. Biol. Chem. (1993) 268:6119–6124.
   PubMed Web of Science ®Google Scholar
• FRANK KB, NOLL GJ, CONNELL EV, SIM IS: Kinetic inter-action of human inununodefidency virus type 1 re-verse transcriptase with the antiviral tetrahydrohnidazo[4,5,111411,4]-benzodiazepine-2-(1 H)-thione compound, R82150. J. Biol. Chem. (1991) 266:14232–14236.
   PubMed Web of Science ®Google Scholar
• GOLDMAN ME, NUNBERG III, O'BRIEN JA et al.: Pyridinone derivatives: specific human immunodefidency virus type 1 reverse transcriptase inhibitors with antivi-ral activity. Proc. Natl. Acad. Sci. USA (1991) 88:6863–6867.
   Google Scholar
• TAYLOR PB, CULP JS, DEBOUCK C et al.: Kinetic and mutational analysis of human immunodeficiency virus type 1 reverse transcriptase inhibition by inophyllums, a novel class of non-nucleoside inhibitors. J. Biol. Chem. (1994) 269:6325–6331.
   PubMed Web of Science ®Google Scholar
• TRAMONTANO E, CHENG YC: HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587. Biochem. Pharrnacol. (1992) 43:1371–1376.
   PubMed Web of Science ®Google Scholar
• CARROLL SS, OLSEN DB, BENNETT CD et al: Inhibition of •HIV-I reverse transcriptase by pyridinone derivatives. Potency, binding characteristics, and effect of template sequence. J. Biol. Chem. (1993) 268:276–281.
   Google Scholar
• PALLADINO DEH, HOPKINS JL, INGRAHAM RH et al.: High-performance liquid chromatography and photo affinity crosslinking to explore the binding eniviron-ment of nevirapine to reverse transcriptase of human immunodeficiency virus type-1. J. Chromatography (1994) 676:99–112.
   Web of Science ®Google Scholar
• WU JC, WARREN TC, ADAMS J et al.: A novel dipyri-docilazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. Biochemistry (1991) 30: 2022-2026.
   Google Scholar
• MELLORS JW, DUTSCHMAN GE, IM GJ et al.: In vitro selection and molecular characterization of human immunodefidency virus-1 resistant to nonnucleoside Inhibitors of reverse transcriptase. Mol. Pharmacol. (1992) 41:446–451.
   PubMed Web of Science ®Google Scholar
• NUNBERG JH, SCHLEIF WA, BOOTS EJ et al.: Viral resis-tance to human inununodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J. Vim!. (1991) 65:4887–4892.
   Web of Science ®Google Scholar
• RICHMAN D, SHIH CK, LOWY I et al.: Human irruxtunode ficiency virus type 1 mutants resistant to nonnucleoside Inhibitors of reverse transcriptase arise in tissue cul-ture. Proc. Natl. Acad. Sci. USA (1991) 88:11241–11245.
   Google Scholar
• BALZARINI J, KARLSSON A, PEREZ-PEREZ MJ et al.: HIV-1-specific reverse transcriptase inhibitors show differen-tial activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse tran-scriptase. Virology (1993) 192:246–253.
   PubMed Web of Science ®Google Scholar
• REN J, ESNOUF R, GARMAN E et al.: High resolution structures of HIV-1 RT from four RT-inhibhor com-plexes. Struct. Biol. (1995) 2:293–302.
   Google Scholar
• DING J, DAS K, TANTILLO C et al.: Structure of HIV-1 reverse transcriptase in a complex with the non-nu-cleoside inhibitor alpha-APA R 95845 at 2.8 À resolution. Structure (1995) 3:365–379.
   Google Scholar
• REN J, ESNOUF R, HOPKINS A et al.: The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TU30: lessons for inhibitor design. Structure (1995) 3:915–926.
   Google Scholar
• DING J, DAS K, MOEREELSH et al.: Structure of HIV–1RT/TI130 R 86183 complex reveals similarity in the binding of diverse nonnudeoside inhibitors. Struct. Biol. (1995) 2:407–415.
   Google Scholar
• ESNOUF R, REN J, ROSS C et al.: Mechanism of inhibition of HIV-1 reverse transcriptase by nommdeoside Struct. Biol. (1995) 2:303–308.
   Google Scholar
• SPENCE RA, KATI WM, ANDERSON KS, JOHNSON KA: Mechanism of inhibition of HIV-1 reverse transcriptaseby nonnucleoside inhibitors. Science (1995) 267:988–993.
   Google Scholar
• GOPALAKRISHNAN V, BENKOVIC S: Effect of a thiobenzimidazolone derivative on DNA strand trans-fer catalysed by IHV-1 reverse transcriptase. J. Biol. Chem. (1994) 269:4110–4115.
   PubMed Web of Science ®Google Scholar
• RITTINGER K, DIVITA G, GOODY RS: Human immunode-ficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibi-tion by nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA (1995) 92:8046–8049.
   Google Scholar
• SAAG MS, EMINI EA, LASKIN OL et al.: A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor ofHIV-1 reverse transcriptase. New Engl. J. Med. (1993) 329:1065–1072.
   Google Scholar
• RICHMAN DD, HAVLIR D, CORBEIL J et al.: Nevirapineresistance mutations of human immunodeficiency vi-rus type 1 selected during therapy. J. Vim!. (1994) 68:1660–1666.
   Web of Science ®Google Scholar
• LARDER BA, KENIP SD: Multiple mutations in HIV-1reverse transcriptase confer high-level resistance to zidovudine (AZT). Science (1989) 246:1155–1158.
   PubMed Web of Science ®Google Scholar
• TANTILLO C, DING J, JACOBO-MOLINA A et al.: Locations of anti-AIDS drug binding sites and resistance muta-tions in the three-dimensional structure of HIV-1 reverse transcriptase. j Mol. Biol. (1994) 243:369–387.
   Google Scholar
• SHIH CK, ROSE JM, HANSEN GL et al.: Chimeric humanimmunodeficiency virus type 1/type 2 reverse tran-scriptases display reversed sensitivity to nonnucleoside analogue inhibitors. Proc. Natl. Acad. Sci. USA (1991) 88:9878–9882.
   Google Scholar
• CONDRA JH, EMINI EA, GOTLIB L et al.: Identification of he human immunodeficiency virus reverse transcrip-tase residues that contribute to the activity of diverse nonnucleoside inhibitors. Antimicrob. Agents Chemother. (1992) 36:1441–1446.
   Google Scholar
• BACOLLA A, SHIH CK, ROSE JM et al.: Amino acid substi-tutions in WV-1 reverse transcriptase with correspond-ing residues from HIV-2. Effect on kinetic constants and Inhibition by non-nucleoside analogues. J. Biol. Chem. (1993) 268:16571–16577.
   Google Scholar
• SARDANA VV, EMINI EA, GOTLIB L et al.: Functionalanalysis of HIV-1 reverse transcriptase amino adds Involved in resistance to multiple nonnucleoside in-hibitors. J. Biol. Chem. (1992) 267:17526–17530.
   PubMed Web of Science ®Google Scholar
• SPENCE RA, ANDERSON KS, JOHNSON KA: HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors. Biochemistry (1996) 35:1054–1063.
   Google Scholar
• DEBYSER Z, DE VREESE K, KNOPS-GERRFFS PP et al.:Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immu-nodeficiency virus type 1-specific reverse transcriptase Inhibitors. Mol. Pharmacol. (1993) 43:521–526.
   PubMed Web of Science ®Google Scholar
• LOYA S, BA1CHANASHVILI M, TAR R et al.: Enzymaticproperties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181 to isoleucine and tyrosine 188 to leucine), resistant to nonnucleoside inhibitors. AIDS Research & Human Retroviruses (1994) 10:939–946.
   Google Scholar
• DELARUE M, POCH O, TORDO N, DINO M, ARGOS P: Anattempt to vilify the structure of polymerases. Protein Engin. (1990) 3:461–467.
   PubMedGoogle Scholar
• VANDAMME AM, DEBYSER Z, PAUWELS R et al.: Charac-terization of HIV-1 strains isolated from patients treated with T1E10 R82913. AIDS Research & Human Retroviruses (1994) 10:39–46.
   PubMed Web of Science ®Google Scholar
• PIALOUX G, YOULE M, DUPONT B et al.: Pharmacolcinet-ics of R82913 in patients with AIDS or AIDS related complex. lancet (1991) 338:140–143.
   Google Scholar
• BALZARINI J, KARLSSON A, PEREZ-PEREZ MJ et al.: Knock-ing-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Virology (1993) 196:576–585.
   Google Scholar
• HAVLIR D, CHEESEMAN SH, MCLAUGHLIN M et al.: High-dose nevirapine: safety, pharmacokinetics, and antivi-ral effect in patients with human Mununodeficiency virus infection. J. Infect. Dis. (1995) 171:537–545.
   PubMed Web of Science ®Google Scholar
• SMITH MBK, ROUZER CA, TANEYHILL LA et al. Molecular modelling studies of MV-1 reverse transcriptase non-nucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity. Protein Science (1995) 4:2203–2222.
   PubMed Web of Science ®Google Scholar
• JACQUES PS, WOHRL BM, OTTMANN M, DARLIX JL, LE-GRICE SFJ: Mutating the 'primer grip' of p66 reverse transcriptase implicates tryptophan-229 in template-primer utilization. J. Biol. Chem. (1994) 269:26472–26478.
   PubMed Web of Science ®Google Scholar
• RICHMAN D, ROSENTHAL AS, SKOOG M et al.: BI-RG-587Is active against zidovudine-resistant human immu-nodeficiency virus type 1 and synergistic with zi-dovudine. Antimicrob. Agents Chemother. (1991) 35:305–308.
   PubMed Web of Science ®Google Scholar
• PAUWELS R, ANDRIES K, DEBYSER Z et al.: New tetrahdroimidazo [4,5,11,k][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogues. Antimicrob. Agents Chemother. (1994) 38:2863–2870.
   PubMed Web of Science ®Google Scholar
• BABA M, ITO M, SHIGETA S et al.: Synergistic inhibitionof human immunodeficiency virus type 1 replication by 5-ethyl-1-ethoxymethy1-6-(phenylthio)uracil (e-epu) and azidothymidine in vitro. Antimicrob. Agents Chemother. (1991) 35:1430–1433.
   Google Scholar
• ROMERO DL, BUSSO M, TAN CK et al.: Nonnucleoside reverse transcriptase inhibitors that potently and spe-cifically block human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA (1991) 88:8806–8810.
   Google Scholar
• DE JONG MD, LOEWENTHAL M, BOUCHER CAB et al.: Alternating nevirapine and zidovuditie treatment of human immunodeficiency virus type 1-infected per-sons does not prolong nevirapine activity. J. Infect. Dis. (1994) 169:1346–1350.
   PubMed Web of Science ®Google Scholar
• LARDER BA: 3'-Azido-3'-deoxythymidine resistance sup-pressed by a mutation conferring human immunodefi-ciency virus type 1 resistance to notmucleosicle reverse transcriptase inhibitors. Antimicrob. Agents Chemother. (1992) 36:2664–2669.
   PubMed Web of Science ®Google Scholar
• ST. CLAIR MH, MARTIN JL, TUDOR-WILLIAMS G et al.:Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science (1991) 253:1557–1559.
   Google Scholar
• CHOW YK, HIRSCH MS, MERRILL DP et al.: Use of evolu-tionary limitations of MV-1 multidrug resistance to optimize therapy. Nature (1993) 361:650–654.
   PubMed Web of Science ®Google Scholar
• CHOW Y, HIRSCH MS, KAPLAN JC, D'AQUILA RT: HIV-1 error revealed. Nature (1993) 364:679.
   PubMedGoogle Scholar
• EMINI EA, GRAHAM DJ, GOTLIB L et al.: HIV and multi-drug resistance [Letter; comment]. Nature (1993) 364:679.
   PubMedGoogle Scholar
• LARDER BA, KELLAM P, KEMP SD: Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature (1993) 365:451–453.
   Google Scholar
• CALIENDO AM AND HIRSCH MS: Combination therapy for infection due to human immunodeficiency virus type 1 [Review]. Clin. Infect. Dis. (1994) 18:516–524.
   PubMed Web of Science ®Google Scholar
• ST. CLAIR MH, PENNINGTON KN, ROONEY J, BARRY DW: In vitro comparison of selected triple-drug combina-tions for suppression of HIV-1 replicatiom the inter-company collaboration protocoL J. AIDS & Human Retrovirology (1995) 10\(Suppl. 2):S83–S91.
   Google Scholar
• VELAZQUEZ S, ALVAREZ R, SAN-FELD:( A et al.: Synthesis and anti-HIV activity of [AZT]-[TSAO] and [AZT]-[HEPT] dirtters as potential multifunctional inhibitors of HIV-1 reverse transcriptase. J. Med. Chem. (1995) 38:1641–1649.
   Google Scholar
• FURMAN PA, FYFE JA, ST. CLAIR MD et al.: Phosphoryla-tion of 3'-azido-3'-deoxythymidine and selective inter-action of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA (1986) 83:8333.
   Google Scholar
• BABA M, TANAKA H, DE CLERCQ E eta!: Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem. Biophys. Res. Commun. (1989) 165:1375–1381.
   PubMed Web of Science ®Google Scholar
• PAUWELS R, ANDRLES K, DEBYSER Z et al.: Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenyl-acetamide derivatives targeted at HIV-1 reverse tran-scriptase. Proc. Natl. Acad. Sci. USA (1993) 90:1711–1715.
   PubMed Web of Science ®Google Scholar
• VELAZQUEZ S, SAN-FELIX A, PEREZ-PEREZ MJ et al.: 2',5'-Bis-0-(tert-butyldimethylsily1)-B-D-ribofuranosyl 3'-spiro-5"-(4"-amino-1",2"-oxathiole2",2"-dioxide)purine and purine-modified nucleosides. J. Med. Chem. (1993) 36:3230–3239.
   PubMed Web of Science ®Google Scholar